APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pomalidomide

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pomalidomide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025195 pages

Choose your research edition.

Industry ResearchPomalidomide Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Pomalidomide Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Pomalidomide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pomalidomide Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Pomalidomide Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pomalidomide market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pomalidomide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pomalidomide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pomalidomide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pomalidomide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pomalidomide include Celgene, Chia Tai-Tianqing, Cipla, Dr Reddy's Laboratories, Hanson Pharm, Indiabulls pharmaceutical, Intas Pharmaceuticals, Meidakang Huakang Pharmaceutical and Natco Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pomalidomide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pomalidomide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pomalidomide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pomalidomide market size, projected growth trends, production technologies, key applications, and end-use industries.

Pomalidomide Segment by Company

Celgene

Chia Tai-Tianqing

Cipla

Dr Reddy's Laboratories

Hanson Pharm

Indiabulls pharmaceutical

Intas Pharmaceuticals

Meidakang Huakang Pharmaceutical

Natco Pharma

SL PHARM

Glenmark Pharmaceuticals

Qilu Pharmaceutical

Shandong Kongfu Pharmaceutical

Pomalidomide Segment by Type

1mg Tables

2mg Tables

4mg Tables

Pomalidomide Segment by Application

Clinic

Hospital

Drug Center

Others

Pomalidomide Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pomalidomide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pomalidomide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pomalidomide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pomalidomide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pomalidomide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pomalidomide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pomalidomide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pomalidomide Industry Trends Table 2. Pomalidomide Industry Drivers Table 3. Pomalidomide Industry Opportunities and Challenges Table 4. Pomalidomide Industry Restraints Table 5. Global Pomalidomide Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pomalidomide Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pomalidomide Sales by Manufacturers (k pcs) & (2021-2026) Table 8. Global Pomalidomide Sales Market Share by Manufacturers Table 9. Global Pomalidomide Average Sales Price (US$/pcs) of Manufacturers (2021-2026) Table 10. Global Pomalidomide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pomalidomide Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pomalidomide Manufacturers, Product Type & Application Table 13. Global Pomalidomide Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pomalidomide by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 1mg Tables Table 17. Major Manufacturers of 2mg Tables Table 18. Major Manufacturers of 4mg Tables Table 19. Global Pomalidomide Sales by Type 2021 VS 2025 VS 2032 (k pcs) Table 20. Global Pomalidomide Sales by Type (2021-2026) & (k pcs) Table 21. Global Pomalidomide Sales by Type (2027-2032) & (k pcs) Table 22. Global Pomalidomide Sales Market Share by Type (2021-2026) Table 23. Global Pomalidomide Sales Market Share by Type (2027-2032) Table 24. Global Pomalidomide Revenue by Type 2021 VS 2025 VS 2032 (k pcs) Table 25. Global Pomalidomide Revenue by Type (2021-2026) & (k pcs) Table 26. Global Pomalidomide Revenue by Type (2027-2032) & (k pcs) Table 27. Global Pomalidomide Revenue Market Share by Type (2021-2026) Table 28. Global Pomalidomide Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Drug Center Table 32. Major Manufacturers of Others Table 33. Global Pomalidomide Sales by Application 2021 VS 2025 VS 2032 (k pcs) Table 34. Global Pomalidomide Sales by Application (2021-2026) & (k pcs) Table 35. Global Pomalidomide Sales by Application (2027-2032) & (k pcs) Table 36. Global Pomalidomide Sales Market Share by Application (2021-2026) Table 37. Global Pomalidomide Sales Market Share by Application (2027-2032) Table 38. Global Pomalidomide Revenue by Application 2021 VS 2025 VS 2032 (k pcs) Table 39. Global Pomalidomide Revenue by Application (2021-2026) & (k pcs) Table 40. Global Pomalidomide Revenue by Application (2027-2032) & (k pcs) Table 41. Global Pomalidomide Revenue Market Share by Application (2021-2026) Table 42. Global Pomalidomide Revenue Market Share by Application (2027-2032) Table 43. Global Pomalidomide Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 44. Global Pomalidomide Sales by Region (2021-2026) & (k pcs) Table 45. Global Pomalidomide Sales Market Share by Region (2021-2026) Table 46. Global Pomalidomide Sales Forecasted by Region (2027-2032) & (k pcs) Table 47. Global Pomalidomide Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Pomalidomide Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 49. North America Pomalidomide Sales by Country (2021-2026) & (k pcs) Table 50. North America Pomalidomide Sales by Country (2027-2032) & (k pcs) Table 51. Europe Pomalidomide Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 52. Europe Pomalidomide Sales by Country (2021-2026) & (k pcs) Table 53. Europe Pomalidomide Sales by Country (2027-2032) & (k pcs) Table 54. Asia Pacific Pomalidomide Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 55. Asia Pacific Pomalidomide Sales by Country (2021-2026) & (k pcs) Table 56. Asia Pacific Pomalidomide Sales by Country (2027-2032) & (k pcs) Table 57. South America, Middle East and Africa Pomalidomide Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 58. South America, Middle East and Africa Pomalidomide Sales by Country (2021-2026) & (k pcs) Table 59. South America, Middle East and Africa Pomalidomide Sales by Country (2027-2032) & (k pcs) Table 60. Global Pomalidomide Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Pomalidomide Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Pomalidomide Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Pomalidomide Revenue Market Share by Region (2021-2026) Table 64. Global Pomalidomide Revenue Market Share by Region (2027-2032) Table 65. Celgene Company Information Table 66. Celgene Business Overview Table 67. Celgene Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Celgene Pomalidomide Product Portfolio Table 69. Celgene Recent Development Table 70. Chia Tai-Tianqing Company Information Table 71. Chia Tai-Tianqing Business Overview Table 72. Chia Tai-Tianqing Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Chia Tai-Tianqing Pomalidomide Product Portfolio Table 74. Chia Tai-Tianqing Recent Development Table 75. Cipla Company Information Table 76. Cipla Business Overview Table 77. Cipla Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Cipla Pomalidomide Product Portfolio Table 79. Cipla Recent Development Table 80. Dr Reddy's Laboratories Company Information Table 81. Dr Reddy's Laboratories Business Overview Table 82. Dr Reddy's Laboratories Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Dr Reddy's Laboratories Pomalidomide Product Portfolio Table 84. Dr Reddy's Laboratories Recent Development Table 85. Hanson Pharm Company Information Table 86. Hanson Pharm Business Overview Table 87. Hanson Pharm Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Hanson Pharm Pomalidomide Product Portfolio Table 89. Hanson Pharm Recent Development Table 90. Indiabulls pharmaceutical Company Information Table 91. Indiabulls pharmaceutical Business Overview Table 92. Indiabulls pharmaceutical Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Indiabulls pharmaceutical Pomalidomide Product Portfolio Table 94. Indiabulls pharmaceutical Recent Development Table 95. Intas Pharmaceuticals Company Information Table 96. Intas Pharmaceuticals Business Overview Table 97. Intas Pharmaceuticals Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Intas Pharmaceuticals Pomalidomide Product Portfolio Table 99. Intas Pharmaceuticals Recent Development Table 100. Meidakang Huakang Pharmaceutical Company Information Table 101. Meidakang Huakang Pharmaceutical Business Overview Table 102. Meidakang Huakang Pharmaceutical Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Meidakang Huakang Pharmaceutical Pomalidomide Product Portfolio Table 104. Meidakang Huakang Pharmaceutical Recent Development Table 105. Natco Pharma Company Information Table 106. Natco Pharma Business Overview Table 107. Natco Pharma Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Natco Pharma Pomalidomide Product Portfolio Table 109. Natco Pharma Recent Development Table 110. SL PHARM Company Information Table 111. SL PHARM Business Overview Table 112. SL PHARM Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. SL PHARM Pomalidomide Product Portfolio Table 114. SL PHARM Recent Development Table 115. Glenmark Pharmaceuticals Company Information Table 116. Glenmark Pharmaceuticals Business Overview Table 117. Glenmark Pharmaceuticals Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Glenmark Pharmaceuticals Pomalidomide Product Portfolio Table 119. Glenmark Pharmaceuticals Recent Development Table 120. Qilu Pharmaceutical Company Information Table 121. Qilu Pharmaceutical Business Overview Table 122. Qilu Pharmaceutical Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Qilu Pharmaceutical Pomalidomide Product Portfolio Table 124. Qilu Pharmaceutical Recent Development Table 125. Shandong Kongfu Pharmaceutical Company Information Table 126. Shandong Kongfu Pharmaceutical Business Overview Table 127. Shandong Kongfu Pharmaceutical Pomalidomide Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Shandong Kongfu Pharmaceutical Pomalidomide Product Portfolio Table 129. Shandong Kongfu Pharmaceutical Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Pomalidomide Distributors List Table 133. Pomalidomide Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Pomalidomide Product Image Figure 2. Global Pomalidomide Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pomalidomide Market Size (2021-2032) & (US$ Million) Figure 4. Global Pomalidomide Sales (2021-2032) & (k pcs) Figure 5. Global Pomalidomide Average Price (US$/pcs) & (2021-2032) Figure 6. Global Top 5 and 10 Pomalidomide Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 1mg Tables Image Figure 9. 2mg Tables Image Figure 10. 4mg Tables Image Figure 11. Global Pomalidomide Sales by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 12. Global Pomalidomide Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Pomalidomide Sales Market Share by Type (2021-2032) Figure 14. Global Pomalidomide Revenue by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 15. Global Pomalidomide Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Pomalidomide Revenue Market Share by Type (2021-2032) Figure 17. Clinic Image Figure 18. Hospital Image Figure 19. Drug Center Image Figure 20. Others Image Figure 21. Global Pomalidomide Sales by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 22. Global Pomalidomide Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Pomalidomide Sales Market Share by Application (2021-2032) Figure 24. Global Pomalidomide Revenue by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 25. Global Pomalidomide Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Pomalidomide Revenue Market Share by Application (2021-2032) Figure 27. North America Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 28. North America Pomalidomide Sales Market Share by Country (2021-2032) Figure 29. U.S. Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 30. Canada Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 31. Mexico Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 32. Europe Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 33. Europe Pomalidomide Sales Market Share by Country (2021-2032) Figure 34. Germany Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 35. France Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 36. U.K. Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 37. Italy Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 38. Netherlands Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 39. Asia Pacific Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 40. Asia Pacific Pomalidomide Sales Market Share by Country (2021-2032) Figure 41. China Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 42. Japan Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 43. South Korea Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 44. Southeast Asia Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 45. India Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 46. Australia Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 47. South America, Middle East and Africa Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 48. South America, Middle East and Africa Pomalidomide Sales Market Share by Country (2021-2032) Figure 49. Brazil Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 50. South Africa Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 51. Saudi Arabia Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 52. Turkey Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 53. Argentina Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 54. UAE Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 55. Egypt Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 56. Chile Pomalidomide Sales and Growth Rate (2021-2032) & (k pcs) Figure 57. Global Pomalidomide Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Pomalidomide Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Pomalidomide Revenue (2021-2032) & (US$ Million) Figure 60. North America Pomalidomide Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Pomalidomide Revenue (2021-2032) & (US$ Million) Figure 62. Europe Pomalidomide Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Pomalidomide Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Pomalidomide Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Pomalidomide Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Pomalidomide Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Pomalidomide Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Pomalidomide Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 1mg Tables
  • 2mg Tables
  • 4mg Tables
Applications
  • Clinic
  • Hospital
  • Drug Center
  • Others
Companies covered
  • Celgene
  • Chia Tai-Tianqing
  • Cipla
  • Dr Reddy's Laboratories
  • Hanson Pharm
  • Indiabulls pharmaceutical
  • Intas Pharmaceuticals
  • Meidakang Huakang Pharmaceutical
  • Natco Pharma
  • SL PHARM
  • Glenmark Pharmaceuticals
  • Qilu Pharmaceutical
  • Shandong Kongfu Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pomalidomide Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pomalidomide Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pomalidomide Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pomalidomide Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pomalidomide Market Dynamics
  1. 2.1 Pomalidomide Industry Trends
  2. 2.2 Pomalidomide Industry Drivers
  3. 2.3 Pomalidomide Industry Opportunities and Challenges
  4. 2.4 Pomalidomide Industry Restraints
3 Pomalidomide Market by Manufacturers
  1. 3.1 Global Pomalidomide Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pomalidomide Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pomalidomide Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pomalidomide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pomalidomide Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pomalidomide Manufacturers, Product Type & Application
  7. 3.7 Global Pomalidomide Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pomalidomide Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pomalidomide Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pomalidomide Tier 1, Tier 2, and Tier 3
4 Pomalidomide Market by Type
  1. 4.1 Pomalidomide Type Introduction
  2. 4.1.1 1mg Tables
  3. 4.1.2 2mg Tables
  4. 4.1.3 4mg Tables
  5. 4.2 Global Pomalidomide Sales by Type
  6. 4.2.1 Global Pomalidomide Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pomalidomide Sales by Type (2021-2032)
  8. 4.2.3 Global Pomalidomide Sales Market Share by Type (2021-2032)
  9. 4.3 Global Pomalidomide Revenue by Type
  10. 4.3.1 Global Pomalidomide Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pomalidomide Revenue by Type (2021-2032)
  12. 4.3.3 Global Pomalidomide Revenue Market Share by Type (2021-2032)
5 Pomalidomide Market by Application
  1. 5.1 Pomalidomide Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Drug Center
  5. 5.1.4 Others
  6. 5.2 Global Pomalidomide Sales by Application
  7. 5.2.1 Global Pomalidomide Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Pomalidomide Sales by Application (2021-2032)
  9. 5.2.3 Global Pomalidomide Sales Market Share by Application (2021-2032)
  10. 5.3 Global Pomalidomide Revenue by Application
  11. 5.3.1 Global Pomalidomide Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Pomalidomide Revenue by Application (2021-2032)
  13. 5.3.3 Global Pomalidomide Revenue Market Share by Application (2021-2032)
6 Global Pomalidomide Sales by Region
  1. 6.1 Global Pomalidomide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pomalidomide Sales by Region (2021-2032)
  3. 6.2.1 Global Pomalidomide Sales by Region (2021-2026)
  4. 6.2.2 Global Pomalidomide Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pomalidomide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pomalidomide Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pomalidomide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pomalidomide Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pomalidomide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pomalidomide Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pomalidomide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pomalidomide Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pomalidomide Revenue by Region
  1. 7.1 Global Pomalidomide Revenue by Region
  2. 7.1.1 Global Pomalidomide Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pomalidomide Revenue by Region (2021-2026)
  4. 7.1.3 Global Pomalidomide Revenue by Region (2027-2032)
  5. 7.1.4 Global Pomalidomide Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pomalidomide Revenue (2021-2032)
  8. 7.2.2 North America Pomalidomide Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pomalidomide Revenue (2021-2032)
  11. 7.3.2 Europe Pomalidomide Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pomalidomide Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pomalidomide Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pomalidomide Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pomalidomide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Celgene
  2. 8.1.1 Celgene Company Information
  3. 8.1.2 Celgene Business Overview
  4. 8.1.3 Celgene Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Celgene Pomalidomide Product Portfolio
  6. 8.1.5 Celgene Recent Developments
  7. 8.2 Chia Tai-Tianqing
  8. 8.2.1 Chia Tai-Tianqing Company Information
  9. 8.2.2 Chia Tai-Tianqing Business Overview
  10. 8.2.3 Chia Tai-Tianqing Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Chia Tai-Tianqing Pomalidomide Product Portfolio
  12. 8.2.5 Chia Tai-Tianqing Recent Developments
  13. 8.3 Cipla
  14. 8.3.1 Cipla Company Information
  15. 8.3.2 Cipla Business Overview
  16. 8.3.3 Cipla Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cipla Pomalidomide Product Portfolio
  18. 8.3.5 Cipla Recent Developments
  19. 8.4 Dr Reddy's Laboratories
  20. 8.4.1 Dr Reddy's Laboratories Company Information
  21. 8.4.2 Dr Reddy's Laboratories Business Overview
  22. 8.4.3 Dr Reddy's Laboratories Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dr Reddy's Laboratories Pomalidomide Product Portfolio
  24. 8.4.5 Dr Reddy's Laboratories Recent Developments
  25. 8.5 Hanson Pharm
  26. 8.5.1 Hanson Pharm Company Information
  27. 8.5.2 Hanson Pharm Business Overview
  28. 8.5.3 Hanson Pharm Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hanson Pharm Pomalidomide Product Portfolio
  30. 8.5.5 Hanson Pharm Recent Developments
  31. 8.6 Indiabulls pharmaceutical
  32. 8.6.1 Indiabulls pharmaceutical Company Information
  33. 8.6.2 Indiabulls pharmaceutical Business Overview
  34. 8.6.3 Indiabulls pharmaceutical Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Indiabulls pharmaceutical Pomalidomide Product Portfolio
  36. 8.6.5 Indiabulls pharmaceutical Recent Developments
  37. 8.7 Intas Pharmaceuticals
  38. 8.7.1 Intas Pharmaceuticals Company Information
  39. 8.7.2 Intas Pharmaceuticals Business Overview
  40. 8.7.3 Intas Pharmaceuticals Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Intas Pharmaceuticals Pomalidomide Product Portfolio
  42. 8.7.5 Intas Pharmaceuticals Recent Developments
  43. 8.8 Meidakang Huakang Pharmaceutical
  44. 8.8.1 Meidakang Huakang Pharmaceutical Company Information
  45. 8.8.2 Meidakang Huakang Pharmaceutical Business Overview
  46. 8.8.3 Meidakang Huakang Pharmaceutical Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Meidakang Huakang Pharmaceutical Pomalidomide Product Portfolio
  48. 8.8.5 Meidakang Huakang Pharmaceutical Recent Developments
  49. 8.9 Natco Pharma
  50. 8.9.1 Natco Pharma Company Information
  51. 8.9.2 Natco Pharma Business Overview
  52. 8.9.3 Natco Pharma Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Natco Pharma Pomalidomide Product Portfolio
  54. 8.9.5 Natco Pharma Recent Developments
  55. 8.10 SL PHARM
  56. 8.10.1 SL PHARM Company Information
  57. 8.10.2 SL PHARM Business Overview
  58. 8.10.3 SL PHARM Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SL PHARM Pomalidomide Product Portfolio
  60. 8.10.5 SL PHARM Recent Developments
  61. 8.11 Glenmark Pharmaceuticals
  62. 8.11.1 Glenmark Pharmaceuticals Company Information
  63. 8.11.2 Glenmark Pharmaceuticals Business Overview
  64. 8.11.3 Glenmark Pharmaceuticals Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Glenmark Pharmaceuticals Pomalidomide Product Portfolio
  66. 8.11.5 Glenmark Pharmaceuticals Recent Developments
  67. 8.12 Qilu Pharmaceutical
  68. 8.12.1 Qilu Pharmaceutical Company Information
  69. 8.12.2 Qilu Pharmaceutical Business Overview
  70. 8.12.3 Qilu Pharmaceutical Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Qilu Pharmaceutical Pomalidomide Product Portfolio
  72. 8.12.5 Qilu Pharmaceutical Recent Developments
  73. 8.13 Shandong Kongfu Pharmaceutical
  74. 8.13.1 Shandong Kongfu Pharmaceutical Company Information
  75. 8.13.2 Shandong Kongfu Pharmaceutical Business Overview
  76. 8.13.3 Shandong Kongfu Pharmaceutical Pomalidomide Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Shandong Kongfu Pharmaceutical Pomalidomide Product Portfolio
  78. 8.13.5 Shandong Kongfu Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pomalidomide Value Chain Analysis
  2. 9.1.1 Pomalidomide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pomalidomide Production Mode & Process
  6. 9.2 Pomalidomide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pomalidomide Distributors
  9. 9.2.3 Pomalidomide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst